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Abstract
Age-related macular degeneration (AMD) is a debilitating, common cause of visual impairment. While the last
decade has seen great progress in understanding the pathophysiology of AMD, the molecular changes that occur
in eyes with AMD are still poorly understood. In the current issue of Genome Medicine, Newman and colleagues
present the first systematic transcriptional profile analysis of AMD-affected tissues, providing a comprehensive set
of expression data for different regions (macula versus periphery), tissues (retina versus retinal pigment epithelium
(RPE)/choroid), and disease state (control versus early or advanced AMD). Their findings will serve as a foundation
for additional systems-level research into the pathogenesis of this blinding disease.
Please see related article: http://genomemedicine.com/content/4/2/16
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Background
Age-related macular degeneration (AMD) is a progres-
sive, complex disease, representing the most common
cause of legal blindness in the developed world. In the
United States alone, the prevalence of any type of AMD
in individuals over the age of 40 is conservatively about
6.5%, or 7.2 million [1]. Risk factors for AMD include
age, smoking, and a number of genetic polymorphisms.
Early stages of AMD are clinically characterized by
changes in retinal pigment epithelium (RPE) pigmenta-
tion and accumulation of drusen, extracellular deposits
beneath the RPE. In some patients, AMD progresses to
severe retinal atrophy and/or the pathologic growth of
blood vessels from the choroid into the retina, a destruc-
tive process called choroidal neovascularization (CNV)
(Figure 1). For reasons not completely understood, these
events are predominantly localized to the macula, a spe-
cialized region of the retina that performs the crucial task
of delivering sharp, central vision. Loss of macular photo-
receptor cells results in inability to read, drive, or recog-
nize faces. Several biological processes have been
implicated in the pathogenesis of AMD, including
complement-activation [2], inflammation [3], and oxida-
tive stress [4].
While the last decade has seen great progress in under-
standing the pathophysiology of AMD, the molecular
changes that occur in eyes with AMD are still poorly
understood. The study of AMD is complicated by the
limitations of animal models (for example, apart from
primates, mammals lack a specialized macula), necessitat-
ing the use of human tissue. Anti-angiogenic drugs have
been used to suppress CNV; however, no treatments are
currently available to halt AMD prior to irreversible ret-
inal damage, although dietary modulation may provide
some benefit [5,6]. Identification of potential therapies
may be facilitated by high-throughput systems biological
analyses, particularly at the proteome and transcriptome
levels.
Previous studies assessing mRNA levels in normal
h u m a nr e t i n a ,R P E ,a n dc h o r o i d revealed tissue-specific
molecular signatures [7,8] and differences between macu-
lar and extramacular transcript expression [9-13]. How-
ever, systematic transcriptional profiling had not been
performed on AMD affected tissues, and the overall
molecular phenotypes of AMD have not been thoroughly
examined.
In the current issue of Genome Medicine,N e w m a n
and colleagues address this gap. The authors compared
gene expression of 37 AMD eyes (divided into categories
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Expression profiling was performed for both the neural
retina and the combined RPE/choroid layers of the eye
using an oligonucleotide microarray platform. These
experiments uncovered distinct molecular signatures for
each assigned AMD class, termed disease modules, as
well as a set of differentially regulated genes shared by
all classes. By overlapping disease modules with existing
protein association data, Newman et al.c o n s t r u c t e d
interaction networks (interactomes) for AMD in RPE/
choroid and retina.
Discussion
Identification of disease modules associated with AMD
grade
Standard differential expression analysis produced only a
small number of statistically significant genes associated
with AMD classes. The authors then relaxed their filter-
ing criteria and computationally identified modules of
genes within and among AMD classes, tissue types, and
anatomical regions (macula and periphery) based on
coordinate expression and putative shared biological
function. This elegant clustering method, designed to
detect patterns confounded by background variation,
revealed that the RPE/choroid in eyes with CNV showed
increased expression of genes associated with angiogenic
processes (such as VCAM1 and WNT4), whereas sam-
ples with geographic atrophy (GA) were enriched for
apoptosis-related genes (such as caspases).
In both the RPE/choroid and retina, genes elevated
across all AMD grades were enriched for regulators of
cell-mediated immunity. In the RPE/choroid, these
included immunoglobulin genes, a number of cytokines,
and several CD antigens associated with T cell activation.
These findings provide strong support for the concept
that the microenvironment in AMD eyes is pro-inflam-
matory, with increased numbers and/or activities of leu-
kocytes that may be responsible for injury to resident
RPE or choroidal cells. Moreover, the elevation of these
transcripts at the earliest stages of AMD, even before dis-
ease may be clinically identified, may suggest early oppor-
tunities for therapeutic management, which would be a
major advance.
Prediction of AMD status based on common molecular
signature
One potentially important metric to validate the molecu-
l a rs i g n a t u r e so ft h eA M De y e si st od e t e r m i n et h ep r e -
dictive power of the disease modules to correctly assign
new samples into the appropriate group. The authors
constructed a computational classification model based
on the twenty most significant genes from the globally
upregulated RPE/choroid module. After training the
model on subsets of the original cohort of microarrays,
Newman et al. tested it on a second cohort of 47 micro-
arrays. The model performed well, correctly classifying
an average of 71% of the samples in the second cohort as
either ‘AMD’ or ‘normal. This result supports the finding
of a globally upregulated set of genes across AMD stages
in the RPE/choroid.
Functional enrichment of genes within protein
interactomes
A hallmark of many systems-level studies is the integra-
tion of large datasets with molecular networks. These
models become frameworks for further analyses, such as
the identification of pathologically altered pathways or
the discovery of central modulators of network function,
which may serve as drug targets. Newman et al.u s e d
genes from statistically significant disease modules to
retrieve protein association relationships from online
interaction repositories. From this information, they con-
structed interactomes for RPE/choroid and retina. Data
regarding macular versus extramacular expression and
disease progression was then overlaid on the network.
Both interactomes were significantly enriched for genes
previously associated with AMD. In the macular retina,
phototransduction elements decreased expression with
increasing AMD severity. This measured decrease likely
results from the loss of rod and cone photoreceptor cells
observed in advanced AMD (for example, Figure 1D, E).
Areas for additional study
W h i l et h es t u d yb yN e w m a net al. is notable as the first
transcriptomics study to systematically analyze AMD
cases and to so do with a very large sample cohort, sev-
eral issues remain to be addressed by the field. Presum-
ably, most of the mRNA changes detected will result in
altered levels of their gene products. However, the rela-
tionship between changes in mRNA expression and pro-
tein production are not always linear. For example, a
recent study analyzed gene expression in porcine tissues
using three platforms (two that interrogated RNA levels
and one that quantified proteins) [15]. By comparing the
ratios of positively correlated genes common to the three
technologies, the authors found good correspondence
between transcript ratios and protein ratios for about
75% of these genes, with approximately 25% showing
poor correspondence. Thus, integration of transcriptome
profiling, as presented by Newman et al., with new and
previously published proteomics surveys of AMD tissue
[16-18] may resolve which transcripts are translated
directly or are under post-transcriptional regulation.
In addition, methods are now available to assess not only
the total abundance of mRNA molecules encoded by a
gene, but also their specific transcripts and novel isoforms
[19,20]. Distinct splicing isoforms of several genes are
associated with both inherited and acquired diseases [21]
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Figure 1 Structural features of eyes with AMD.( A) Schematic of human eye with the macular region indicated by the bracket. (B-E)
Histological sections of eyes from individuals with normal retina (B); drusen (asterisks) beneath the RPE, a sign of early stage AMD (C);
geographic atrophy with loss of photoreceptor cells (D); and choroidal neovascularization, with pathologic angiogenesis beneath the retina and
RPE (E). The paper by Newman and colleagues explored gene expression differences in neural retina and the RPE/choroid layers based on
disease state and region in an unprecedented number of eyes. asterisks, drusen; arrowheads in E, pathologic blood vessels. AMD, age-related
macular degeneration; CH, choroid; CNVM, choroidal neovascular membrane; NR, neural retina; RPE, retinal pigment epithelium.
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molecules may reveal novel regulatory mechanisms.
There are several potential sources for transcriptional
signals that vary between affected and unaffected tissues,
including: altered expression of the gene within resident
cells; degeneration of a cell type in disease that contributes
a specific transcript in the healthy organ; and increased
migration/proliferation of a cell type such that a new syn-
thetic source for the mRNA has been introduced. The ele-
vation of cellular immunity genes in all stages of AMD is
very interesting, and may represent altered behavior of
resident RPE/choroidal cells and/or the introduction of
increased numbers of leukocytes in the choroid of eyes
with AMD, as described previously with immunohisto-
chemistry [22,23]. As Newman and colleagues point out,
identifying the cellular source(s) of the AMD-associated
transcripts will be important extensions of this work.
Finally, a clearer picture has emerged over the last sev-
eral years of how variants in genes associated with the
complement pathways influence risk of AMD [24]. An
extension of the excellent studies by Newman and collea-
gues would be comparing the transcriptome of anatomi-
cally healthy eyes at genetically low- or high-risk for
developing AMD. Identifying altered patterns of comple-
ment proteins has been explored in human tissues with
known AMD-associated genotypes [25,26]. Systems based
analysis of tissues with different genotypes may uncover
the initial molecular events in eyes predisposed to disease,
even before the genesis of any overt pathology.
Conclusions
The study by Newman et al. is a major contribution to the
community, providing a comprehensive set of data for
region-based (macular versus extramacular), tissue-based
(retina versus RPE/choroid), and disease-based (control
versus early, atrophic, and neovascular AMD) expression.
Their findings will serve as a foundation for additional sys-
tems-level research including integration with proteomics,
assessment of alternatively spliced transcripts, identifica-
tion of novel transcripts, and determination of cell-specific
contributions to gene expression. Systems-level
approaches such as these will aid in unraveling the patho-
genesis of this complex, blinding disorder.
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